NCT05146284View on ClinicalTrials.gov

Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Adrenomyeloneuropathy
Interventions
DRUG

PXL770

Tablet

Sponsors

Lead Sponsor

Poxel SA
All Listed Sponsors
lead

Poxel SA

INDUSTRY

NCT05146284 - Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) | Biotech Hunter | Biotech Hunter